Vaxart (VXRT) announced its common stock has been approved to trade on the OTCQX Best Market. The Company’s shares will commence trading at the open of the market on July 8, 2025, under its existing ticker symbol “VXRT.” Shareholders will not need to take any action. The OTCQX Market, being the highest tier of OTC Markets Group, enables Vaxart to provide the greatest transparency, visibility, and accessibility to investors available in the OTC Markets. In addition, after receiving a delisting notice from Nasdaq, Vaxart has requested a hearing before a Nasdaq Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), Vaxart’s common stock remains suspended pending a decision from the Nasdaq Hearings Panel.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VXRT:
- OTC Markets Group welcomes Vaxart to OTCQX
- Vaxart Stockholders Reject Reverse Stock Split Proposal
- Vaxart’s Promising Developments and Market Potential Justify Buy Rating
- Vaxart Announces Positive Phase 1 Norovirus Vaccine Results
- Vaxart reports results from Phase 1 trial of second-gen norovirus vaccine